SEC Company Response from Liminal BioSciences Inc. (CIK 0001351172) — Dec 7, 2020
Liminal BioSciences Inc. (CIK 0001351172)
Date: Dec. 7, 2020 · CIK: 0001351172 · Accession: 0001564590-20-056304
AI Filing Summary & Sentiment
File numbers found in text: 333-251055, 333-251065
Letter
lmnl-corresp.htm
LIMINAL BIOSCIENCES INC.
440 Armand-Frappier Boulevard, Suite 300
Laval, Québec
H7V 4B4
December 7, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re:
Liminal BioSciences Inc.
Registration Statements on Form F-3
File No. 333-251055 and File No. 333-251065
Acceleration Request
Requested Date:
December 8, 2020
Requested Time:
4:00 p.m., Eastern time
Ladies and Gentlemen:
The undersigned registrant hereby requests that the staff of the U.S. Securities and Exchange Commission take appropriate action to cause the Registration Statements on Form F-3 (File Nos. 333-251055 and 333-251065) to become effective on December 8, 2020, at 4:00 p.m., Eastern time, or as soon as practicable thereafter.
Very truly yours,
Liminal BioSciences Inc.
Show Raw Text
CORRESP
1
filename1.htm
lmnl-corresp.htm
LIMINAL BIOSCIENCES INC.
440 Armand-Frappier Boulevard, Suite 300
Laval, Québec
H7V 4B4
December 7, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re:
Liminal BioSciences Inc.
Registration Statements on Form F-3
File No. 333-251055 and File No. 333-251065
Acceleration Request
Requested Date:
December 8, 2020
Requested Time:
4:00 p.m., Eastern time
Ladies and Gentlemen:
The undersigned registrant hereby requests that the staff of the U.S. Securities and Exchange Commission take appropriate action to cause the Registration Statements on Form F-3 (File Nos. 333-251055 and 333-251065) to become effective on December 8, 2020, at 4:00 p.m., Eastern time, or as soon as practicable thereafter.
Very truly yours,
Liminal BioSciences Inc.
By:
/s/ Murielle Lortie
Name: Murielle Lortie
Title: Chief Financial Officer
cc:
Marie Iskra, Liminal BioSciences Inc.
Murielle Lortie, Liminal BioSciences Inc.
Jaime L. Chase, Cooley LLP
Richard Segal, Cooley LLP
Divakar Gupta, Cooley LLP